ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,081 to 4,100 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Gepotidacin vs Nitrofurantoin: Number of Participants With Treatment-emergent Adverse Events (TEAEs)285 of 804

200 of 798

10.4 points

5.9 to 14.8

1,602NCT04187144

Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)

Gepotidacin vs Nitrofurantoin: Number of Participants With Serious Adverse Events (SAEs)5 of 804

5 of 798

-0.0 points

-0.9 to 0.9

1,602NCT04187144

Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)

Gepotidacin vs Nitrofurantoin: serious adverse events5 of 804

5 of 798

-0.0 points

-0.9 to 0.9

1,602NCT04187144

Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)

Acute Pain - Immediate PGx Testing vs Acute Pain - Delayed PGx Testing: deaths from any cause1 of 801

2 of 801

-0.1 points

-0.8 to 0.5

1,602NCT05966129

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Acute Pain Trial)

300 IR vs Placebo: serious adverse events21 of 800

9 of 801

1.5 points

0.2 to 3.0

1,601NCT02443805

Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR

Dabigatran 220mg vs Enoxaparin: Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period18 of 805

33 of 795

-1.9 points

-3.7 to -0.2

1,600NCT00657150

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

Regional Anesthesia vs General Anesthesia: Major Inpatient Morbidity98 of 795

120 of 805

-2.6 points

-5.9 to 0.8

1,600NCT02507505

Regional Versus General Anesthesia for Promoting Independence After Hip Fracture

Regional Anesthesia vs General Anesthesia: deaths from any cause98 of 795

92 of 805

0.9 points

-2.3 to 4.1

1,600NCT02507505

Regional Versus General Anesthesia for Promoting Independence After Hip Fracture

Regional Anesthesia vs General Anesthesia: serious adverse events255 of 795

242 of 805

2.0 points

-2.5 to 6.5

1,600NCT02507505

Regional Versus General Anesthesia for Promoting Independence After Hip Fracture

IDeg U200 vs IGlar U300: deaths from any cause7 of 802

9 of 798

-0.3 points

-1.4 to 0.8

1,600NCT03078478

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

IDeg U200 vs IGlar U300: serious adverse events167 of 802

141 of 798

3.2 points

-0.7 to 7.0

1,600NCT03078478

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

Evolocumab in Parent Study vs Placebo in Parent Study: deaths from any cause51 of 855

35 of 745

1.3 points

-1.0 to 3.5

1,600NCT03080935

Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Oral Anticoagulant (Control) vs WATCHMAN FLX DEVICE: ISTH Major Bleeding38 of 797

30 of 803

1.0 points

-1.0 to 3.1

1,600NCT03795298

Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

Oral Anticoagulant (Control) vs WATCHMAN FLX DEVICE: Primary Safety Endpoint: Non-procedural Bleeding137 of 797

65 of 803

9.1 points

5.9 to 12.3

1,600NCT03795298

Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

Oral Anticoagulant (Control) vs WATCHMAN FLX DEVICE: deaths from any cause35 of 797

31 of 803

0.5 points

-1.5 to 2.5

1,600NCT03795298

Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

Oral Anticoagulant (Control) vs WATCHMAN FLX DEVICE: Primary Effectiveness Endpoint: Stroke, All Cause Death, and Systemic Embolism44 of 797

41 of 803

0.4 points

-1.8 to 2.7

1,600NCT03795298

Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

Oral Anticoagulant (Control) vs WATCHMAN FLX DEVICE: serious adverse events797 of 797

803 of 803

0.0 points

-0.5 to 0.5

1,600NCT03795298

Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study vs Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study: Number of Participants Who Experienced an Adverse Event810 of 854

686 of 745

2.8 points

0.3 to 5.3

1,599NCT03080935

Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Evolocumab in Parent Study vs Placebo in Parent Study: serious adverse events410 of 854

323 of 745

4.7 points

-0.2 to 9.5

1,599NCT03080935

Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Intervention - Nocturnal Coverage vs Control - Standard of Care: MICU Mortality154 of 820

139 of 778

0.9 points

-2.9 to 4.7

1,598NCT01434823

24 Hour Intensivist Coverage in the Medical Intensive Care Unit

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=205"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=205

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04187144-6cb4949c",
        "title": "Gepotidacin vs Nitrofurantoin: Number of Participants With Treatment-emergent Adverse Events (TEAEs)",
        "summary": "285 of 804 against 200 of 798; risk difference 10.4 points, 95% interval 5.9 to 14.8; NCT04187144, Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)",
        "record": "/library/comparisons/NCT04187144-6cb4949c",
        "nct_id": "NCT04187144",
        "kind": "outcome",
        "participants": 1602,
        "risk_difference": {
          "value": 0.10385104552425845,
          "lower": 0.05893160675830204,
          "upper": 0.14818638007792148
        },
        "group_1": "285 of 804",
        "group_2": "200 of 798",
        "difference": "10.4 points",
        "interval": "5.9 to 14.8",
        "trial_title": "Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)"
      },
      {
        "id": "NCT04187144-ca85f5ef",
        "title": "Gepotidacin vs Nitrofurantoin: Number of Participants With Serious Adverse Events (SAEs)",
        "summary": "5 of 804 against 5 of 798; risk difference -0.0 points, 95% interval -0.9 to 0.9; NCT04187144, Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)",
        "record": "/library/comparisons/NCT04187144-ca85f5ef",
        "nct_id": "NCT04187144",
        "kind": "outcome",
        "participants": 1602,
        "risk_difference": {
          "value": -0.00004675868776418592,
          "lower": -0.00909373963353553,
          "upper": 0.00895439764563561
        },
        "group_1": "5 of 804",
        "group_2": "5 of 798",
        "difference": "-0.0 points",
        "interval": "-0.9 to 0.9",
        "trial_title": "Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=206",
  "request_id": "jO2Jz6apcYOZ_9iU"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?